About Us
Aurora was founded to address a defining challenge in rare disease: while more than 
350 million people worldwide are affected, most lack treatments that target their specific genetic mutations. Traditional development models cannot scale to thousands of rare variants, leaving the vast majority of patients without options.
Aurora exists to change this reality by transforming personalized gene editing from isolated, heroic efforts into a systematic, scalable approach capable of reaching patients with any disease variant.
Our team brings together leaders in gene editing, rare-disease medicine, regulatory science, and therapeutic development who have already demonstrated what personalized gene editing can achieve. They are building the first platform designed for many-at-a-time development, driven by their shared passion to realize the potential of personalized gene editing for millions of patients with rare diseases.
LEADERSHIP
Edward M Kaye, M.D.
Chief Executive Officer
David Litvak, M.B.A.
Head of CMC and Technical Operations
Morgan Maeder, Ph.D.
Head of Research
FOUNDERS
Jennifer Doudna, Ph.D.
Li Ka Shing Chancellor’s Chair and a Professor in the Departments of Chemistry and of Molecular and Cell Biology at the University of California, Berkeley; Howard Hughes Medical Institute investigator; President and Chair of the board of the Innovative Genomics Institute
Fyodor Urnov, Ph.D.
Professor of Molecular Therapeutics at University of California, Berkeley; Scientific Director of the Innovative Genomics Institute
BOARD OF DIRECTORS
Johnny Hu, Ph.D. (Chair)
Principal at Menlo Ventures
Greg Yap, M.B.A.
Partner at Menlo Ventures
Edward M Kaye, M.D.
Chief Executive Officer